Skip to main content

Table 1 General characteristics of H1N1 vaccine recipients and controls

From: Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals

  Unvaccinated (n = 12) Vaccinated (n = 81) Responders (n = 36) Non-responders (n = 44)
aCD4+ T cells/μL Mean ± SD 420 ± 235 529 ± 269 609 ± 277 475 ± 241
0–200 1 (8.3%) 9 (11%) 3 (8.3%) 5 (11%)
201–350 5 (42%) 13 (16%) 4 (11%) 9 (20%)
351–500 2 (17%) 15 (19%) 4 (11%) 11 (25%)
>500 4 (33%) 44 (54%) 25 (69%) 19 (43%)
Log10 viral load Median (IQR) 1.60 (1.60-2.09) 1.60 (1.60-2.70) 1.60 (1.60-2.34) 1.60 (1.60-3.07)
≤1.60 8 (67%) 50 (62%) 23 (64%) 27 (61%)
1.61-2.60 3 (25%) 11 (14%) 7 (19%) 4 (9.1%)
2.61-3.00 0 2 (2.5%) 1 (2.8%) 1 (2.3%)
3.01-4.00 0 6 (7.4%) 1 (2.8%) 5 (11%)
>4.00 1 (8.3%) 12 (14%) 4 (11%) 7 (16%)
Age (years) Mean ± SD 45.7 ± 6.6 45.2 ± 7.2 44.2 ± 7.5 46.2 ± 7.0
Male 8 (67%) 56 (69%) 27 (75%) 29 (66%)
Female 4 (33%) 25 (31%) 9 (25%) 16 (36%)
bPre-existing anti-H1N1 ND 28 (35%) 22 (61%) 6 (14%)
  1. aNumber of CD4+ T cells/μL peripheral blood at time nearest to, but before H1N1 vaccination.
  2. bNumber of individuals in each group with antibodies against H1N1 HA before vaccination.